Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 5/2017

01-09-2017 | Original Article

miR-668 enhances the radioresistance of human breast cancer cell by targeting IκBα

Authors: Ming Luo, Ling Ding, Qingjian Li, Herui Yao

Published in: Breast Cancer | Issue 5/2017

Login to get access

Abstract

Background

A large proportion of breast cancer patients are resistant to radiotherapy, which is a mainstay treatment for this malignancy, but the mechanisms of radioresistance remain unclear.

Methods and materials

To evaluate the role of miRNAs in radioresistance, we established two radioresistant breast cancer cell lines MCF-7R and T-47DR derived from parental MCF-7 and T-47D. Moreover, miRNA microarray, quantitative RT-PCR analysis, luciferase reporter assay and western blotting were used.

Results

We found that miR-668 was most abundantly expressed in radioresistant cells MCF-7R and T-47DR. miR-668 knockdown reversed radioresistance of MCF-7R and T-47DR, miR-668 overexpression enhanced radioresistance of MCF-7 and T-47D cells. Mechanically, bioinformatics analysis combined with experimental analysis demonstrated IκBα, a tumor-suppressor as well as an NF-κB inhibitor, was a direct target of miR-668. Further, miR-668 overexpression inhibited IκBα expression, activated NF-κB, thus, increased radioresistance of MCF-7 and T-47D cells. Conversely, miR-668 knockdown restored IκBα expression, suppressed NF-κB, increased radiosensitivity of MCF-7R and T-47DR cells.

Conclusion

Our findings suggest miR-668 is involved in the radioresistance of breast cancer cells and miR-668-IκBα-NF-κB axis may be a novel candidate for developing rational therapeutic strategies for human breast cancer treatment.
Literature
1.
Ahn SJ, Choi C, Choi YD, Kim YC, Kim KS, Oh IJ, et al. Microarray analysis of gene expression in lung cancer cell lines treated by fractionated irradiation. Anticancer Res. 2014;34(9):4939–48.PubMed
2.
Burstein HJ, Morrow M. Nodal irradiation after breast-cancer surgery in the era of effective adjuvant therapy. N Engl J Med. 2015;373(4):379–81.CrossRefPubMed
3.
But-Hadzic J, Bilban-Jakopin C, Hadzic V. The role of radiation therapy in locally advanced breast cancer. Breast J. 2010;16(2):183–8.CrossRefPubMed
4.
Chen XY, Wang Z, Li B, Zhang YJ, Li YY. Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells. Biochem Biophys Res Commun. 2016;473(1):296–302.CrossRefPubMed
5.
6.
Fu ZC, Wang FM, Cai JM. Gene expression changes in residual advanced cervical cancer after radiotherapy: indicators of poor prognosis and radioresistance? Med Sci Monit. 2015;21:1276–87.CrossRefPubMedPubMedCentral
7.
Gong C, Nie Y, Qu S, Liao JY, Cui X, Yao H, et al. miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Cancer Res. 2014;74(16):4341–52.CrossRefPubMed
8.
Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011;286(21):19127–37.CrossRefPubMedPubMedCentral
9.
Hein AL, Post CM, Sheinin YM, Lakshmanan I, Natarajan A, Enke CA, et al. RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene. 2016;35(49):6319–29.CrossRefPubMedPubMedCentral
10.
Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, et al. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget. 2015;6(26):22439–51.CrossRefPubMedPubMedCentral
11.
Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis. 2015;20(9):1242–52.CrossRefPubMed
12.
Kurth I, Hein L, Mabert K, Peitzsch C, Koi L, Cojoc M, et al. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget. 2015;6(33):34494–509.PubMedPubMedCentral
13.
Lan F, Yue X, Ren G, Li H, Ping L, Wang Y, et al. miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-kappaB signaling pathway. Int J Radiat Oncol Biol Phys. 2015;91(1):73–81.CrossRefPubMed
14.
Li J, Huang H, Sun L, Yang M, Pan C, Chen W, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009;15(12):3998–4008.CrossRefPubMed
15.
Liang DH, El-Zein R, Dave B. Autophagy inhibition to increase radiosensitization in breast cancer. J Nucl Med Radiat Ther. 2015;6(5):1–13.CrossRef
16.
Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2(11):1113–20.PubMed
17.
Liao H, Xiao Y, Hu Y, Xiao Y, Yin Z, Liu L. microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncol Lett. 2015;10(4):2055–62.PubMedPubMedCentral
18.
Mazurik VK, Moroz BB. Problems of radiobiology and p53 protein. Radiat Biol Radioecol. 2001;41(5):548–72.
19.
McIlrath J, Bouffler SD, Samper E, Cuthbert A, Wojcik A, Szumiel I, et al. Telomere length abnormalities in mammalian radiosensitive cells. Cancer Res. 2001;61(3):912–5.PubMed
20.
Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016;7(40):64820–35.PubMedPubMedCentral
21.
Oh ET, Byun MS, Lee H, Park MT, Jue DM, Lee CW, et al. Aurora-A contributes to radioresistance by increasing NF-κB DNA binding. Radiat Res. 2010;174(3):265–73.CrossRefPubMed
22.
Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA. 2001;98(4):1676–81.CrossRefPubMedPubMedCentral
23.
Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, et al. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 2012;11(4):785–96.CrossRefPubMedPubMedCentral
24.
Qu JQ, Yi HM, Ye X, Li LN, Zhu JF, Xiao T, et al. MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway. Oncotarget. 2015;6(29):28341–56.CrossRefPubMed
25.
Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB, Bossola M. Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer. 2010;46(1):191–7.CrossRefPubMedPubMedCentral
26.
Ropars V, Despouy G, Stern MH, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-κB inhibitor IκB. PLoS ONE. 2009;4(8):e6567.CrossRefPubMedPubMedCentral
27.
28.
Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH. MicroRNA and cancer: tiny molecules with major implications. Curr Genom. 2008;9(2):97–109.CrossRef
29.
Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194–204.CrossRefPubMed
30.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed
31.
Zand H, Rahimipour A, Salimi S, Shafiee SM. Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-κB suppression. Mol Cell Biochem. 2008;317(1–2):113–20.CrossRefPubMed
32.
Zhao F, Ming J, Zhou Y, Fan L. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother Pharmacol. 2016;77(5):963–72.CrossRefPubMed
33.
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L, et al. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. J Transl Med. 2015;13:252–65.CrossRefPubMedPubMedCentral
Metadata
Title
miR-668 enhances the radioresistance of human breast cancer cell by targeting IκBα
Authors
Ming Luo
Ling Ding
Qingjian Li
Herui Yao
Publication date
01-09-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0756-1

Other articles of this Issue 5/2017

Breast Cancer 5/2017 Go to the issue

Original Article

What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?

Original Article

Digital volumetric measurement of mammographic density and the risk of overlooking cancer in Japanese women

Original Article

Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells

Erratum

Erratum to: Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements

Original Article

Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer

Original Article

The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits